This product is an acetanilide antipyretic analgesic. It inhibits cyclooxygenase and selectively inhibits the synthesis of prostaglandins in the hypothalamic temperature regulation center, leading to peripheral vasodilation and sweating to achieve an antipyretic effect. Its antipyretic effect is similar to that of aspirin. It inhibits the synthesis and release of prostaglandins, etc., increases the pain threshold and has an analgesic effect. It is a peripheral analgesic, weaker than aspirin, and is only effective for mild and moderate pain. This product has no obvious anti-inflammatory effect.

By implanting dominant bacteria into the wound surface, a biofilm can be quickly formed, which has a biological antagonistic effect, acting as a biological barrier and antibacterial effect on the burn wound surface, thereby achieving the purpose of preventing and treating exogenous infections such as Staphylococcus aureus, Pseudomonas aeruginosa, and Pseudomonas aeruginosa.

By implanting dominant bacteria into the wound surface, a biofilm can be quickly formed, which has a biological antagonistic effect, acting as a biological barrier and antibacterial effect on the burn wound surface, thereby achieving the purpose of preventing and treating exogenous infections such as Staphylococcus aureus, Pseudomonas aeruginosa, and Pseudomonas aeruginosa.

Cough and asthma medicine

Cough and asthma medicine

Cough and asthma medicine

Cough and asthma medicine

Cough and asthma medicine

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.